Newsroom | 227813 results
Sorted by: Latest
-
Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals
LAKE ZURICH, Ill. & BETHESDA, Md.--(BUSINESS WIRE)--Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) announced today the launch of the 21st annual Blood Collectors Week, taking place September 6–12, 2026. The annual recognition week celebrates the blood collection professionals whose expertise and dedication help ensure patients across the country have access to safe, high-quality blood and blood components. Blood Collectors Week honors the essential pro...
-
Evinova and Lothar Medical Announce Strategic Partnership to Modernise Respiratory Clinical Trials with Unified Trial Solution
BAAR, Switzerland--(BUSINESS WIRE)--Evinova, a global leader in AI-native clinical development technology, today announced a strategic partnership with Lothar Medical to help transform the execution of respiratory clinical trials globally. Through the agreement, Evinova’s Unified Trial Solution will integrate with Lothar Medical’s respiratory devices to support a more connected, data-rich trial experience for sponsors, sites, and patients. Evinova Unified Trial Solution is a globally scaled, GxP...
-
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s ETCAMAH® (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, based on a US Food and Drug Administration (FDA)-authorized test...
-
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with ESR1 mutations before radiographic progression who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca’s next-gener...
-
Laird Superfood Appoints Mark Johnson as Chief Financial Officer
BOULDER, Colo.--(BUSINESS WIRE)--Laird Superfood, Inc. (NYSE American: LSF) today announced the appointment of Mark Johnson as Chief Financial Officer, effective October 1, 2026. Mr. Johnson will report to Chief Executive Officer Jason Vieth and will serve as the Company’s principal financial officer and principal accounting officer.Mr. Johnson brings more than 25 years of finance leadership across public consumer packaged goods and private equity-backed companies. He joins Laird Superfood from...
-
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo. Consistent with previous studies, substan...
-
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 38,330 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on September 1, 2026 (the “Grant Date”). The Indu...
-
Project Santa Fe Foundation Expands Leadership With Three Distinguished New Board Members to Advance Predictive, Value-Based Laboratory Medicine
SALT LAKE CITY--(BUSINESS WIRE)--Three Trailblazers Join PSFF Board and Global Clinical Lab 2.0 Movement...
-
Arkansas Regulators Approve Arkansas Blue Cross and Blue Shield's Affiliation With Cambia Health Solutions
PORTLAND, Ore. & LITTLE ROCK, Ark.--(BUSINESS WIRE)--The Arkansas Insurance Department has approved the strategic affiliation between Arkansas Blue Cross and Blue Shield and Cambia Health Solutions. The affiliation will enable greater capabilities for access to care that is simpler and more affordable, while maintaining the strong local commitment that has served Arkansans for more than 78 years. The affiliation will unify operations and enable the organizations to share best practices and expe...
-
Caring Men Global Announces Rollout and Fall Program Expansion of Strong Caregivers, Stronger Survivors
CHEVY CHASE, Md.--(BUSINESS WIRE)--With Novartis & Exelixis, Caring Men Global expands "Strong Caregivers, Stronger Survivors" to support male caregivers of cancer survivors....